Kaneka Eurogentec Increases GMP Mfg. Capacity for mRNA

Capital investment of 2 billion JPY adds production capacity that is approximately 5 times higher than the current capacity.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Kaneka Corp. is increasing its GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A., a wholly owned group company in Europe. The company plans to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is approximately 5 times higher than the current capacity.    mRNA, which has been used in COVID-19 vaccines, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for gen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters